Who are Dolutegravir + Lamivudine FDC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CAR, JULUCA, Cabotegravir LA + Rilpivirine LA, CAB + RPV, CAB LA + RPV LA, Cabotegravir, Rilpivirine Drug Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dolutegravir-lamivudine-fdc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dolutegravir + Lamivudine FDC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dolutegravir + Lamivudine FDC (Dolutegravir + Lamivudine FDC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination (INSTI + NRTI) HIV integrase and HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Dolutegravir + Lamivudine FDC (Dolutegravir + Lamivudine FDC) — ViiV Healthcare. Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dolutegravir + Lamivudine FDC TARGET	Dolutegravir + Lamivudine FDC	ViiV Healthcare	phase 3	Antiretroviral combination (INSTI + NRTI)	HIV integrase and HIV reverse transcriptase
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
JULUCA	JULUCA	ViiV Healthcare	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase
Cabotegravir LA + Rilpivirine LA	Cabotegravir LA + Rilpivirine LA	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	marketed	Antiretroviral combination (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
CAB + RPV	CAB + RPV	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	phase 3	Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV integrase and HIV reverse transcriptase
CAB LA + RPV LA	CAB LA + RPV LA	ViiV Healthcare	phase 3	Antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV integrase and HIV reverse transcriptase
Cabotegravir, Rilpivirine Drug Combination	Cabotegravir, Rilpivirine Drug Combination	University Paris 7 - Denis Diderot	phase 3	Antiretroviral combination (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTI) class)

ViiV Healthcare · 2 drugs in this class
Denver Infectious Disease Consultants, PLLC · 1 drug in this class
Fundacion SEIMC-GESIDA · 1 drug in this class
Fundação Bahiana de Infectologia · 1 drug in this class
Charlotte-Paige Rolle, MD · 1 drug in this class
Saint Michael's Medical Center · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
Hospitales Universitarios Virgen del Rocío · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dolutegravir + Lamivudine FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/dolutegravir-lamivudine-fdc. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab